


## Zorubicin

<b>Cat. No.:</b>	HY-106556
<b>CAS No.:</b>	54083-22-6
<b>Molecular Formula:</b>	C <sub>34</sub> H <sub>35</sub> N <sub>3</sub> O <sub>10</sub>
<b>Molecular Weight:</b>	645.66
<b>Target:</b>	DNA/RNA Synthesis; Topoisomerase
<b>Pathway:</b>	Cell Cycle/DNA Damage
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Zorubicin (Rubidazon) is a derivative of <a href="#">Daunorubicin</a> (HY-13062A). Zorubicin interacts with topoisomerase II and inhibits DNA polymerases. Zorubicin can be used for the research of acute leukemias and sarcomas <sup>[1][2][3][4][5]</sup> .								
<b>In Vitro</b>	<p>Zorubicin (0.1-1 µg/mL; 0-24 h) affects cell cycle<sup>[2]</sup>.</p> <p>Zorubicin (0-128 nM/mL; 20 min) dose-dependently inhibits DNA polymerases α and β, and shows preferential inhibition of polymerase α<sup>[3]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Cycle Analysis<sup>[2]</sup>.</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Human lymphoid cell line</td> </tr> <tr> <td>Concentration:</td> <td>0.1-1 µg/mL</td> </tr> <tr> <td>Incubation Time:</td> <td>0-24 hours</td> </tr> <tr> <td>Result:</td> <td>Time-dependently increased G2-accumulations of human lymphoid cells, delayed the traverse through G1 and the G1-S transition. Caused a stepwise accumulation of cells in G2-phase.</td> </tr> </table>	Cell Line:	Human lymphoid cell line	Concentration:	0.1-1 µg/mL	Incubation Time:	0-24 hours	Result:	Time-dependently increased G2-accumulations of human lymphoid cells, delayed the traverse through G1 and the G1-S transition. Caused a stepwise accumulation of cells in G2-phase.
Cell Line:	Human lymphoid cell line								
Concentration:	0.1-1 µg/mL								
Incubation Time:	0-24 hours								
Result:	Time-dependently increased G2-accumulations of human lymphoid cells, delayed the traverse through G1 and the G1-S transition. Caused a stepwise accumulation of cells in G2-phase.								
<b>In Vivo</b>	<p>Zorubicin (12-18 mg/kg; i.p. 48 h after tumour cells injection) affects leukaemic colony forming units<sup>[1]</sup>.</p> <p>Zorubicin (0.75-6.0 mg/kg; i.v.) increases plasma histamine concentrations and produces immediate hypotension in anesthetized beagle dogs<sup>[3]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Six- to eight-week-old male DBA<sub>2</sub> mice with P388 tumour cells<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>12-18 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal injection ; 12-18 mg/kg; 48 h after tumour cells injection</td> </tr> <tr> <td>Result:</td> <td>Showed a D<sub>1/2</sub> value of 1.6 mg/kg for leukaemic colony forming units.</td> </tr> </table>	Animal Model:	Six- to eight-week-old male DBA <sub>2</sub> mice with P388 tumour cells <sup>[1]</sup>	Dosage:	12-18 mg/kg	Administration:	Intraperitoneal injection ; 12-18 mg/kg; 48 h after tumour cells injection	Result:	Showed a D <sub>1/2</sub> value of 1.6 mg/kg for leukaemic colony forming units.
Animal Model:	Six- to eight-week-old male DBA <sub>2</sub> mice with P388 tumour cells <sup>[1]</sup>								
Dosage:	12-18 mg/kg								
Administration:	Intraperitoneal injection ; 12-18 mg/kg; 48 h after tumour cells injection								
Result:	Showed a D <sub>1/2</sub> value of 1.6 mg/kg for leukaemic colony forming units.								

---

## REFERENCES

- [1]. Alberts DS, Van Daalen Wetters T. Rubidazole vs adriamycin: an evaluation of their differential toxicity in the spleen colony assay system. *Br J Cancer*. 1976 Jul;34(1):64-8.
- [2]. Barlogie B, et al. Kinetic response to cultured human lymphoid cells to rubidazole. *J Natl Cancer Inst*. 1978 Feb;60(2):279-82.
- [3]. Herman EH, Young RS. Acute cardiovascular alterations induced by low doses of adriamycin, rubidazole, and daunorubicin in the anesthetized beagle dog. *Cancer Treat Rep*.
- [4]. Sartiano GP, et al. Mechanism of action of the anthracycline anti-tumor antibiotics, doxorubicin, daunomycin and rubidazole: preferential inhibition of DNA polymerase alpha. *J Antibiot (Tokyo)*. 1979 Oct;32(10):1038-45.
- [5]. Akerman KJ, et al. Gold(III) macrocycles: nucleotide-specific unconventional catalytic inhibitors of human topoisomerase I. *J Am Chem Soc*. 2014 Apr 16;136(15):5670-82.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA